Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer

Table 1

The clinical characteristics of advanced NSCLC in training and validation cohort ( (%)).

Characteristics	Training set	Validation set
	TCGA ()	GSE41271 ()	GSE81089 ()
Age (year)
<65	82 (42.71)	33 (36.26)	13 (36.11)
≥65	110 (57.29)	58 (63.74)	23 (63.89)
Gender
Male	117 (60.94)	54 (59.34)	14 (38.89)
Female	75 (39.06)	37 (40.66)	22 (61.11)
Histological type
LUAD	104 (54.17)	55 (60.44)	27 (75)
LUSC	88 (45.83)	36 (39.56)	9 (25)
Metastasis (M_stage)
M0	160 (83.33)	85 (93.41)	33 (91.67)
M1	32 (16.67)	6 (6.59)	3 (8.33)
Lymph node (N_stage)
N0	30 (15.63)	—	—
N1	47 (24.48)	—	—
N2	106 (55.21)	—	—
N3	9 (4.69)	—	—
Tumor invasion (T_stage)
T1	21 (10.94)	—	—
T2	85 (44.27)	—	—
T3	45 (23.44)	—	—
T4	41 (21.35)	—	—
Tumor stage
III	160 (83.33)	85 (93.41)	33 (91.67)
IV	32 (16.67)	6 (6.59)	3 (8.33)
Smoking
Yes	166 (86.46)	80 (87.91)	—
No	26 (13.54)	11 (12.09)	—

Abbreviations: LUAD = lung adenocarcinoma; LUSC = lung squamous cell carcinoma.